Hematologic Malignancy
Follicular Lymphoma
CI-CAN-00005316Explore in graph →
Hematologic216 active trials8 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005316Explore in graph →
Clinical trials
775 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (149)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04097067 | ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | unknown | N/A | 83 | University Hospital MuensterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05749549 |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers |
| unknown |
| Phase 1 / Phase 2 |
| 191 |
| Shanghai Blueray Biopharma Co., Ltd.INDUSTRY |
| 1 |
| Aug 7, 2024 |
| clinicaltrials |
| NCT06424379 | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.(BCL6-RINHL) | unknown | — | 135 | Hospices Civils de LyonOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT05387616 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden(Alternative-C) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05284825 | A Phase II Trial of Intermediate Radiation Dose For Lymphoma | unknown | N/A | 27 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05414162 | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | unknown | — | 60 | University Hospital, BonnOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05003141 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | unknown | Phase 1 | 110 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics)INDUSTRY | 3 | Mar 28, 2022 | clinicaltrials |
| NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04952974 | B-cell Chronic Lymphoid Malignancies Markers(MALYZOMA-II) | unknown | — | 420 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04934930 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status(FLMRD) | unknown | Phase 2 | 40 | Meir Medical CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | unknown | Phase 3 | 319 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04842318 | Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | unknown | Phase 4 | 789 | Ruijin HospitalOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02194751 | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | unknown | Phase 2 | 30 | XEME Biopharma Inc.INDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | unknown | Phase 2 | 122 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT04707079 | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT03921879 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 50 | Oncotartis, Inc.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04587388 | Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry(LUPIAE) | unknown | — | 500 | European Hematology Association - Lymphoma GroupOTHER | 6 | Oct 14, 2020 | clinicaltrials |
| NCT04324879 | A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) | unknown | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04370405 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | unknown | Phase 2 | 123 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 11, 2020 | clinicaltrials |
| NCT04379167 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 140 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 7, 2020 | clinicaltrials |
| NCT03600363 | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients | unknown | Phase 2 | 250 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04154228 | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 6, 2019 | clinicaltrials |
| NCT04048395 | Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea(FLPOD24) | unknown | — | 80 | Samsung Medical CenterOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03715309 | R2 in the Treatment of Follicular Lymphoma | unknown | Phase 2 | 115 | Ruijin HospitalOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03999697 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02652910 | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma(MeCAR) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT03221348 | A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma | unknown | Phase 1 | 24 | Cho Pharma Inc.INDUSTRY | 0 | Jan 24, 2018 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01329354 | Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy | unknown | Phase 2 | 38 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT03265158 | Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0(BMPB) | unknown | — | 108 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03234140 | Constitutional Genetics in Follicular Lymphoma(CONPIL) | unknown | — | 1,883 | Hospices Civils de LyonOTHER | 1 | Jul 31, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02721407 | Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients(MendCART) | unknown | Phase 1 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02927717 | An Italian Experience on Grade 3b Follicular Lymphoma(FL3b-Oss-2015) | unknown | — | 60 | A.O.U. Città della Salute e della ScienzaOTHER | 0 | Oct 7, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02791217 | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool | unknown | — | 100 | Assuta Medical CenterOTHER | 0 | Jun 6, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2024source: clinicaltrials